Postdoctoral Scholar, University of California San Francisco (UCSF)
BIOGRAPHY
DEC 09, 2021 8:00 AM PST
Reprogramming human regulatory T cell specificity with a novel anti-HLA-A2 chimeric antigen receptor
Speaker
Event Date & Time
Date: December 9, 2021
Time: 8:00am (PDT), 11:00am (EDT)
Abstract
Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donor-derived human leukocyte antigen (HLA) is a promising strategy to induce immune tolerance to pancreatic islet transplants, the only curative procedure available for type 1 diabetes. Here, we describe a novel anti-HLA-A2 CAR (A2-CAR) created by grafting the complementarity-determining regions (CDRs) of a human monoclonal anti-HLA-A2 antibody into the Herceptin 4D5 single-chain variable fragment and fusing it to a CD28-zeta signaling domain. A2-CAR Tregs were generated either by ablating the endogenous T-cell receptor (TCR) constant region alpha (TRAC) locus via CRISPR/Cas9 and then introducing the A2-CAR by lentiviral transduction, or by directly knocking the A2-CAR gene into the TRAC locus. A2-CAR+TCR- human Tregs maintained Treg phenotype and function in vitro. Moreover, they selectively accumulated in HLA-A2-expressing islets transplanted from either HLA-A2 transgenic mice or deceased human donors into immunodeficient mice. Importantly, A2-CAR+TCR- Tregs did not impair the function of these HLA-A2+ islets, whereas A2-CAR+TCR-CD4+ T effector cells rejected HLA-A2+ islets in less than 2 weeks. In addition, A2-CAR+TCR- Tregs delayed xenogeneic graft-versus-host disease specifically in the presence of HLA-A2 antigen in co-transferred peripheral blood mononuclear cells, the recipient mice, or both. In summary, genome-engineered human A2-CAR Tregs localize to HLA-A2-expressing islet grafts and exhibit antigen-dependent in vivo suppression, independent of TCR expression. This work may inform the development of precision Treg cell-based strategies to assuage islet transplant rejection.
Learning Objectives
- Provide an overview of regulatory T cells
- Discuss and describe chimeric antigen receptors
- Discuss the challenges treating autimmune disease and organ transplant rejection
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...